Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 21, 2023
Efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma
Wilky, et al.
Filter by
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Connective Tissue Oncology Society (CTOS)
Oct 13, 2023
Efficacy and safety of Botensilimab plus Balstilimab combination therapy in refractory metastatic sarcoma patients: findings from an ongoing expanded phase 1b study
Wilky, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Journal of Clinical Oncology
Oct 6, 2023
Accelerating the Evolution of Immune-Related Enterocolitis Management
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Oncogene
Sep 21, 2023
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Phosphopeptide Targets
Nature Communications
Jun 12, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicity
AGEN2373 (CD137 Agonist)
American Society of Clinical Oncology (ASCO)
Jun 3, 2023
A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors
Barve et al.